Amboss, a medical education and clinical decision-making company, has closed a €240m ($259.5m) financing round for broadening its offering to nurses as well as other health care professionals.
This substantial investment will also strengthen the company’s plans to explore other international markets.
Go deeper with GlobalData
The funding round involves new long-term investors KIRKBI, M&G Investments, and Lightrock, along with contributions from existing shareholders.
The company, which recently transitioned to a European stock corporation (SE), is poised to enhance its technology and penetrate new market segments, with selective acquisitions also forming part of its strategic approach.
Amboss co-founder and co-CEO Benedikt Hochkirchen said: “We choose investors who are committed to our long-term vision and very flexible in the investment duration. Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond.”
The financing round comes on the heels of the company’s 2024 acquisition of Novaheal, a nursing field start-up.
At the core of its mission is the digital empowerment of physicians.
The company focuses on integrating the latest medical content with technology, positioning itself as a digital co-pilot for everyday clinical practice.
By offering precise and actionable recommendations on treatment and diagnostics based on the latest guidelines, Amboss aims to save time and reduce treatment errors for healthcare professionals.
KIRKBI Private Capital head Peter Bason said: “We are excited to partner with other experienced technology and growth investors to back Amboss’ visionary leadership team in their mission of empowering the next generation of health care professionals worldwide.”
Amboss was founded in 2012 by a group of physicians and focuses on providing quality content, utilising AI technology, and prioritising user experience.
